Why Cleerly COMPARE
Cleerly COMPARE is a revolutionary feature that empowers physicians to evaluate changes to coronary artery disease (CAD) and helps guide therapeutic decisions to achieve key treatment goals.
Assess changes in plaque over time
Cleerly COMPARE provides longitudinal disease evaluation so providers can assess changes in CAD progression — key to heart attack prevention
Guide personalized treatment
The report from Cleerly COMPARE helps inform treatment decisions, allowing you to individualize therapy to specific patient needs
Human-refined
The AI-generated report is reviewed, refined, and confirmed by a human reviewer to ensure that you’re working with the precise, consistent analysis data
From plaque analysis to lifestyle optimization
- Evaluation and monitoring of plaque, including low-density-non-calcified plaque, non-calcified plaque, and calcified plaque, can help physicians assess a patient’s risk above and beyond stenosis severity and aggregate plaque burden1
- Clinically relevant insights provide a framework for physicians to initiate, intensify, or de-intensify medical management of patients with CAD2
41%
reduction in the rate of death and non-fatal heart attacks in patients with chest pain that receive a CCTA vs patients that did not at 5 years3
Assessing atherosclerosis is challenging due to limitations of current image processing4

The information display of Cleerly COMPARE allows you to easily compare results from one CCTA to the next, with an unprecedented level of detail
Evaluate plaque volume from scan to scan |
In some cases, plaque may regress between scans, indicating that the patient's therapy is effective |
Analyze in lesion-by-lesion detail |
AI-generated. Human-refined.
Taking the Cleerly AI-generated report further with a personalized expert reviewer. Included with the Cleerly COMPARE feature is an added level of analysis by a human reviewer. There is no extra cost for this additional level of review.
-
References
References:
1 Chang HJ, Lin FY, Lee SE, et al. J Am Coll Cardiol. 2018;71(22):2511-2522. doi:10.1016/j.jacc.2018.02.079
2 Min JK, Chang HJ, Andreini D, et al. J Cardiovasc Comput Tomogr. 2022;16(5):415-422. doi:10.1016/j.jcct.2022.03.001
3 Newby DE, Adamson PD, Berry C, et al; SCOT-HEART Investigators. N Engl J Med. 2018;379(10):924-933. doi:10.1056/NEJMoa1805971
Request a Demo
Contact us to see how Cleerly's platform can enhance your diagnostic and prognostic workflow